CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Series A Convertible Preferred Stock Preferred Stock	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance Beginning at Dec. 31, 2021	$ 4,302	$ 37	$ 459,852			$ (410,705)	$ 53,486
Balance Beginning (in shares) at Dec. 31, 2021	4,575	36,790,254		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			3,378				3,378
Exercise of stock options			1,733				1,733
Exercise of stock options (in shares)		225,165
Issuance of stock related to IP license agreement with Ovid			1,169				1,169
Issuance of stock related to IP license agreement with Ovid (in shares)		123,255
Net loss						(19,361)	(19,361)
Balance Ending at Mar. 31, 2022	$ 4,302	$ 37	466,132			(430,066)	40,405
Balance Ending (in shares) at Mar. 31, 2022	4,575	37,138,674		7,307
Balance Beginning at Dec. 31, 2021	$ 4,302	$ 37	459,852			(410,705)	53,486
Balance Beginning (in shares) at Dec. 31, 2021	4,575	36,790,254		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss							(58,794)
Balance Ending at Jun. 30, 2022	$ 4,043	$ 37	470,222			(469,499)	4,803
Balance Ending (in shares) at Jun. 30, 2022	4,300	37,199,150		7,307
Balance Beginning at Mar. 31, 2022	$ 4,302	$ 37	466,132			(430,066)	40,405
Balance Beginning (in shares) at Mar. 31, 2022	4,575	37,138,674		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			3,817				3,817
Net issuance of common stock in connection with the vesting of restricted stock (in shares)		2,508
Exercise of stock options			14				14
Exercise of stock options (in shares)		2,968
Conversion of convertible preferred stock into common	$ (259)		259
Conversion of convertible preferred stock into common stock (in shares)	(275)	55,000
Net loss						(39,433)	(39,433)
Balance Ending at Jun. 30, 2022	$ 4,043	$ 37	470,222			(469,499)	4,803
Balance Ending (in shares) at Jun. 30, 2022	4,300	37,199,150		7,307
Balance Beginning at Dec. 31, 2022	$ 4,043	$ 50	542,428			(430,521)	116,000
Balance Beginning (in shares) at Dec. 31, 2022	4,300	49,642,767		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			3,741				3,741
Net issuance of common stock in connection with the vesting of restricted stock (in shares)		22,350
Unrealized gain on short-term investments					$ 74		74
Net loss						(34,730)	(34,730)
Balance Ending at Mar. 31, 2023	$ 4,043	$ 50	546,169		74	(465,251)	85,085
Balance Ending (in shares) at Mar. 31, 2023	4,300	49,665,117		7,307
Balance Beginning at Dec. 31, 2022	$ 4,043	$ 50	542,428			(430,521)	116,000
Balance Beginning (in shares) at Dec. 31, 2022	4,300	49,642,767		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss							(66,664)
Balance Ending at Jun. 30, 2023		$ 51	554,587		(114)	(497,185)	57,339
Balance Ending (in shares) at Jun. 30, 2023		50,609,182		7,307
Balance Beginning at Mar. 31, 2023	$ 4,043	$ 50	546,169		74	(465,251)	85,085
Balance Beginning (in shares) at Mar. 31, 2023	4,300	49,665,117		7,307
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			3,891				3,891
Net issuance of common stock in connection with the vesting of restricted stock (in shares)		11,625
Exercise of stock options			485				485
Exercise of stock options (in shares)		72,440
Conversion of convertible preferred stock into common	$ (4,043)	$ 1	4,042
Conversion of convertible preferred stock into common stock (in shares)	(4,300)	860,000
Unrealized gain on short-term investments					(188)		(188)
Net loss						(31,934)	(31,934)
Balance Ending at Jun. 30, 2023		$ 51	$ 554,587		$ (114)	$ (497,185)	$ 57,339
Balance Ending (in shares) at Jun. 30, 2023		50,609,182		7,307